In September 2024, Roche, secured FDA approval for an injectable form of its blockbuster multiple sclerosis treatment, Ocrevus, reducing patient treatment time and potentially helping the company stay ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback